Investment analysts at StockNews.com began coverage on shares of Mannatech (NASDAQ:MTEX – Get Rating) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the stock.
Separately, TheStreet lowered shares of Mannatech from a “b-” rating to a “d+” rating in a report on Thursday, April 6th.
Mannatech Price Performance
NASDAQ:MTEX opened at $12.51 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.17 and a quick ratio of 0.68. The firm has a market cap of $23.42 million, a price-to-earnings ratio of -4.98 and a beta of 1.21. The company has a 50 day moving average price of $14.88 and a 200-day moving average price of $17.46. Mannatech has a 1-year low of $11.91 and a 1-year high of $27.99.
Institutional Investors Weigh In On Mannatech
A hedge fund recently raised its stake in Mannatech stock. LSV Asset Management raised its holdings in shares of Mannatech, Incorporated (NASDAQ:MTEX – Get Rating) by 1,090.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,142 shares of the company’s stock after buying an additional 6,542 shares during the quarter. LSV Asset Management owned about 0.37% of Mannatech worth $261,000 as of its most recent SEC filing. Institutional investors and hedge funds own 24.90% of the company’s stock.
About Mannatech
Mannatech, Inc engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L.
Further Reading
- Get a free copy of the StockNews.com research report on Mannatech (MTEX)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.